0.53
-0.1674(-24.12%)
Currency In USD
| Previous Close | 0.69 |
| Open | 0.7 |
| Day High | 0.7 |
| Day Low | 0.53 |
| 52-Week High | 10.61 |
| 52-Week Low | 0.53 |
| Volume | 644,135 |
| Average Volume | 62,268 |
| Market Cap | 1.56M |
| PE | -0.05 |
| EPS | -11.69 |
| Moving Average 50 Days | 0.53 |
| Moving Average 200 Days | 3.8 |
| Change | -0.17 |
If you invested $1000 in Oncternal Therapeutics, Inc. (ONCT) 10 years ago, it would be worth $2.67 as of July 12, 2025 at a share price of $0.527. Whereas If you bought $1000 worth of Oncternal Therapeutics, Inc. (ONCT) shares 5 years ago, it would be worth $11.02 as of July 12, 2025 at a share price of $0.527.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
GlobeNewswire Inc.
Jul 01, 2025 12:00 PM GMT
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
GlobeNewswire Inc.
Mar 07, 2025 9:05 PM GMT
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
GlobeNewswire Inc.
Sep 12, 2024 1:00 PM GMT
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treat